{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T17:03:33Z","timestamp":1789319013500,"version":"build-2803163510"},"reference-count":32,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Risankizumab is administered via a new modality, so-called on-body injector (OBI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the acceptability and the tolerability of OBI-risankizumab therapy, and compare its acceptability with other available modalities in Crohn\u2019s disease (CD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Longitudinal multicenter prospective study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All CD patients from an early access cohort treated with OBI-risankizumab were assessed from the first OBI use (week 0 = W0), W8, W16, and W24. The primary endpoint was acceptability (acceptability numerical scale = ANS). Patients were asked to grade the acceptability of OBI-risankizumab and other modalities of therapeutic maintenance regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 58 CD patients (79.4% with at least four prior advanced therapies), OBI-risankizumab acceptability was 9.5\u00b11.2 at W0 and remained stable until W24 (p=0.97). OBI-risankizumab acceptability showed a higher acceptability than intravenous infusions (p&lt;0.0001), pen injectors (p&lt;0.001), and syringes (p&lt;0.001), and ranked as the preferred route in 64% of patients. OBI-risankizumab Q8 was the most accepted maintenance regimen (ANS = 9.2 \u00b1 2.0), compared to long interval subcutaneous injections (Q12, Q8 or Q4), more frequent injections (weekly or eow), or intravenous infusions every 4\u20138 weeks (p &lt; 0.05 for all comparisons). While 57.4% of patients did not experience any adverse event within 24 weeks, the two most frequent adverse events were mild application-site pain (19.0%) and localized erythema (20.7%) with no need for risankizumab discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>OBI-risankizumab therapy is highly accepted and could be the most preferred maintenance regimen in patients with CD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562848261489118","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:13:41Z","timestamp":1789067621000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Acceptability and tolerability of risankizumab maintenance therapy administered via on-body injector in patients with Crohn\u2019s disease: Results of the ACCEPT-OBI study"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6347-409X","authenticated-orcid":false,"given":"Anthony","family":"Buisson","sequence":"first","affiliation":[{"name":"Universit\u00e9 Clermont Auvergne"},{"name":"CHU Clermont-Ferrand"},{"name":"Universit\u00e9 Clermont Auvergne"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Gebara","sequence":"additional","affiliation":[{"name":"Hopital Saint Eloi Hepatologie Gastro Enterologie"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5748-4841","authenticated-orcid":false,"given":"B\u00e9n\u00e9dicte","family":"Caron","sequence":"additional","affiliation":[{"name":"Nancy University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Boschetti","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Claude Bernard Lyon 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrielle","family":"Gilletta de Saint Joseph","sequence":"additional","affiliation":[{"name":"Hopital Rangueil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Nachury","sequence":"additional","affiliation":[{"name":"INFINITE - Institute for Translational Research in Inflammation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedia","family":"Brixi","sequence":"additional","affiliation":[{"name":"CHU Reims"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Juillerat","sequence":"additional","affiliation":[{"name":"Bern University Hospital"},{"name":"University of Bern"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Serrero","sequence":"additional","affiliation":[{"name":"Hopital Nord, Gastroenterology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucine","family":"Vuitton","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Marie et Louis Pasteur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Hebuterne","sequence":"additional","affiliation":[{"name":"CHU of Nice"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4110-1866","authenticated-orcid":false,"given":"Ludovic","family":"Caillo","sequence":"additional","affiliation":[{"name":"University Hospital of Nimes"},{"name":"University of Montpellier"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Blain","sequence":"additional","affiliation":[{"name":"Institut Mutualiste Montsouris Pathologie Digestive"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4753-6676","authenticated-orcid":false,"given":"David","family":"Laharie","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux Hopital Haut-Leveque Dept. de Gastroenterologie"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-6618","authenticated-orcid":false,"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Digestive Health Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Altwegg","sequence":"additional","affiliation":[{"name":"Hopital Saint Eloi Hepatologie Gastro Enterologie"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8416-5432","authenticated-orcid":false,"given":"Guillaume","family":"Le Cosquer","sequence":"additional","affiliation":[{"name":"Hopital Rangueil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Pereira","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Clermont Auvergne"},{"name":"CHU Clermont-Ferrand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathurin","family":"Fumery","sequence":"additional","affiliation":[{"name":"Amiens University Hospital"},{"name":"Universit\u00e9 de Picardie Jules Verne"},{"name":"Unit\u00e9 Peritox"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.09.015"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-300049"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02586-2"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0b013e3182a19268"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izac119"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00467-6"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00466-4"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314585"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-328052"},{"key":"e_1_3_7_12_2","first-page":"1817","article-title":"Long-term Effectiveness and Safety of Risankizumab in Patients With Crohn\u2019s Disease","volume":"23","author":"Zinger A","year":"2025","unstructured":"Zinger A, Choi D, Choi N, et al. Long-term Effectiveness and Safety of Risankizumab in Patients With Crohn\u2019s Disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2025; 23: 1817\u20131823. https:\/\/doi.org\/10.1016\/j.cgh.2024.09.027","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"e_1_3_7_13_2","first-page":"1336","article-title":"Risankizumab Effectiveness and Safety in Crohn\u2019s Disease: Real-world Data From a Large Tertiary Center","volume":"22","author":"Zinger A","year":"2024","unstructured":"Zinger A, Choi D, Choi N, et al. Risankizumab Effectiveness and Safety in Crohn\u2019s Disease: Real-world Data From a Large Tertiary Center. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2024; 22: 1336\u20131338.e2. https:\/\/doi.org\/10.1016\/j.cgh.2023.11.033","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"e_1_3_7_14_2","first-page":"otaf062","article-title":"Real-World Effectiveness of Risankizumab in Crohn\u2019s Disease: Outcome Data for an IL-23 Inhibitor from the Middle East","volume":"7","author":"Alzaabi MN","year":"2025","unstructured":"Alzaabi MN, Swaid TK, Ahmed HA, et al. Real-World Effectiveness of Risankizumab in Crohn\u2019s Disease: Outcome Data for an IL-23 Inhibitor from the Middle East. Crohns Colitis 2025; 7: otaf062. https:\/\/doi.org\/10.1093\/crocol\/otaf062","journal-title":"Crohns Colitis"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf070"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.4292\/wjgpt.v16.i4.110273"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000047853"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.70783"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izag045"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003969"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-026-09851-4"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000551419"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1159\/000550396"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17358"},{"issue":"24","key":"e_1_3_7_25_2","first-page":"00423","article-title":"Long-term outcome of risankizumab in Crohn\u2019s disease: a real-world GETAID study","volume":"3565","author":"Fumery M","year":"2024","unstructured":"Fumery M, Caron B, H\u00e9buterne X, et al. Long-term outcome of risankizumab in Crohn\u2019s disease: a real-world GETAID study. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2024; 3565(24): 00423.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02477-2"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2023.10.008"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2025.2506808"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001140"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17822"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae015"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21888"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848261489118","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562848261489118","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848261489118","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T16:17:38Z","timestamp":1789316258000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562848261489118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":32,"alternative-id":["10.1177\/17562848261489118"],"URL":"https:\/\/doi.org\/10.1177\/17562848261489118","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"value":"1756-2848","type":"print"},{"value":"1756-2848","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"17562848261489118"}}